These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective? Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR. Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447 [Abstract] [Full Text] [Related]
4. Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis. Wang L, He M, Wang W, Li S, Zhao G. Eur J Pediatr; 2024 Apr; 183(4):1765-1776. PubMed ID: 38240765 [Abstract] [Full Text] [Related]
5. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Youn Y, Kim J, Hong YM, Sohn S. Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981 [Abstract] [Full Text] [Related]
6. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group. Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057 [Abstract] [Full Text] [Related]
7. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, Miyamae T, Yokota S. J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241 [Abstract] [Full Text] [Related]
8. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease. Han CL, Zhao SL. Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902 [Abstract] [Full Text] [Related]
9. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis. Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H. Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059 [Abstract] [Full Text] [Related]
10. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997 [Abstract] [Full Text] [Related]
11. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study). Miura M, Kobayashi T, Igarashi T, Hamada H, Iwata N, Sasaki Y, Matsukawa M, Sato N, Kubo H, Takei S. Pediatr Infect Dis J; 2020 Jan 17; 39(1):41-47. PubMed ID: 31815838 [Abstract] [Full Text] [Related]